在Gracilaria sp.的抗质活性. 乙醇提取物可以预防Plasmodium falciparum
Endah Setyaningrum1, Linda Septiani2, Heri Wibowo3
1Department of Biology, Faculty of Mathematics and Natural Science, Universitas Lampung, Jl Prof Sumantri Brojonegoro 1, 35144 Bandar Lampung, Indonesia.
International maritime health
|September 12, 2025
概括
海藻提取物在抗击疟疾方面表现有前途. 格拉西拉利亚 (Gracilaria) sp. 在 乙醇提取物含有抑制Plasmodium寄生虫生长的化合物,为新药开发提供了潜力.
科学领域:
- 海洋生物学 海洋生物学
- 药理学 药理学是指药理学的学科.
- 寄生虫学的寄生虫学
背景情况:
- 耐药疟疾需要新的治疗策略.
- 海藻是药品生物活性化合物的未经探索的来源.
研究的目的:
- 为了研究Gracilaria sp.的体外抗疟活性. 乙醇提取物. 乙醇提取物.
- 在提取物中识别生物活性化合物,负责抑制虫寄生虫.
主要方法:
- 从干燥的Gracilaria sp.中提取乙醇. 海藻. 海藻.
- 植物化学查,红外光谱学和气色谱学用于化合物识别.
- 在实验室对D37株的Plasmodium falciparum进行检测,以确定IC50值.
主要成果:
- 格拉西拉利亚 (Gracilaria) sp. 在 乙醇提取物中含有沙素,素,黄类和类.
- 类化合物,黄类化合物和其他衍生化合物显示显著抑制了寄生虫增长.
- 提取物呈现的IC50值为43.38微克/毫升,用于抵抗Plasmodium falciparum.
结论:
- 格拉西拉利亚 (Gracilaria) sp. 在 乙醇提取物具有抗疟疾的特性.
- 特定的化合物,如类化合物和黄类化合物,有助于观察到的抗寄生虫活性.
- 这项研究强调海藻是可负担得起的抗疟疾药物开发的潜在来源.
相关概念视频
Malaria
Malaria pathogenesis in humans reflects a delicate interplay between parasite biology and host response. Clinical illness reflects a host’s immune response to the parasite’s asexual replication cycle, which is often asymptomatic in individuals with partial immunity. From the parasite's perspective, transmission between mosquito and human with minimal host pathology is evolutionarily advantageous. Among the six Plasmodium species infecting humans, P. falciparum and P. vivax dominate in global...
Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...


